DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Fanconi anemia complementation group E — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFanconi anemia complementation group E maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fanconi anemia complementation group e is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Fanconi anaemia complementation group E is one of at least eight genetic subtypes of this recessively inherited disease, which is defined at the cellular level by spontaneous chromosomal instability and specific hypersensitivity to DNA cross-linking agents. In 1999, researchers reported that the FANCG protein localises to both the cytoplasm and nucleus and assembles into a physical complex with FANCA. Endogenous FANCA/FANCG complex was detected in non-FA cells and in FA cells from groups D and E, but no complex was detected in cell lines from groups A and G, and reduced levels were found in groups B, C, F, and H. Wild-type levels of the complex were restored upon correction of the cellular phenotype by transfection or cell fusion, suggesting the complex is functionally significant in the FA pathway. A 2001 study examined phosphorylation of FANCA ectopically expressed in FANCA-negative cells; several patient-derived mutations abrogated in vivo phosphorylation, and a cytoplasmic serine kinase sensitive to wortmannin was found to form a complex with FANCA and to be included in the FANCA/FANCG complex.
No abstract in this set reports any drug tested specifically in Fanconi anaemia complementation group E patients. A 1998 review noted that transfection of the normal FA gene into mutant cells corrects hypersensitivity to DNA cross-linking agents and improves cell viability in vitro, and that an experimental gene therapy trial for group C was ongoing at the National Institutes of Health. A 2016 review stated that the molecular mechanism underlying bone marrow failure in Fanconi anaemia had remained elusive and was still a matter of debate. A 2023 literature review summarised that current treatment relies on stem cell transplantation and that more efficient therapies need to be developed.
What is still missing is any drug repurposing data specific to complementation group E, any clinical trial testing a pharmacological intervention in this subgroup, and any patient stratification that would allow a targeted approach. The molecular work from 1999 and 2001 describes a protein complex and a kinase that might be disrupted, but no therapeutic agent has been taken forward from those observations into patients.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Proceedings of the National Academy of Sciences · 1999 · 155 citations · open access
A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA
AbstractFanconi anemia (FA) is a recessively inherited disease characterized at the cellular level by spontaneous chromosomal instability and specific hypersensitivity to cross-linking agents. FA is genetically heterogeneous, comprising at least eight complementation groups (A-H). We report that the protein encoded by the gene mutated in complementation group G (FANCG) localizes to the cytoplasm and nucleus of the cell and assembles in a molecular complex with the FANCA protein, both in vivo and in vitro. Endogenous FANCA/FANCG complex was detected in both non-FA cells and in FA cells from groups D and E. By contrast, no complex was detected in specific cell lines belonging to groups A and G, whereas reduced levels were found in cells from groups B, C, F, and H. Wild-type levels of FANCA/FANCG complex were restored upon correction of the cellular phenotype by transfection or cell fusion experiments, suggesting that this complex is of functional significance in the FA pathway. These results indicate that the cellular FA phenotype can be connected to three biochemical subtypes based on the levels of FANCA/FANCG complex. Disruption of the complex may provide an experimental strategy for chemosensitization of neoplastic cells.
A cytoplasmic serine protein kinase binds and may regulate the Fanconi anemia protein FANCA
AbstractFanconi anemia (FA) is an autosomal recessive disease with congenital anomalies, bone marrow failure, and susceptibility to leukemia. Patient cells show chromosome instability and hypersensitivity to DNA cross-linking agents. At least 8 complementation groups (A-G) have been identified and 6 FA genes (for subtypes A, C, D2, E, F, and G) have been cloned. Increasing evidence indicates that a protein complex assembly of multiple FA proteins, including FANCA and FANCG, plays a crucial role in the FA pathway. Previously, it was reported that FANCA was phosphorylated in lymphoblasts from normal controls, whereas the phosphorylation was defective in those derived from patients with FA of multiple complementation groups. The present study examined phosphorylation of FANCA ectopically expressed in FANCA(-) cells. Several patient-derived mutations abrogated in vivo phosphorylation of FANCA in this system, suggesting that FANCA phosphorylation is associated with its function. In vitro phosphorylation studies indicated that a physiologic protein kinase for FANCA (FANCA-PK) forms a complex with the substrate. Furthermore, at least a part of FANCA-PK as well as phosphorylated FANCA were included in the FANCA/FANCG complex. Thus, FANCA-PK appears to be another component of the FA protein complex and may regulate function of FANCA. FANCA-PK was characterized as a cytoplasmic serine kinase sensitive to wortmannin. Identification of the protein kinase is expected to elucidate regulatory mechanisms that control the FA pathway.
TGF-β: a master regulator of the bone marrow failure puzzle in Fanconi anemia
AbstractFanconi anemia (FA) is a genetic disease mainly characterized by progressive bone marrow failure (BMF), congenital abnormalities, and increased predisposition to cancer (1,2). Although most patients with FA develop BMF generally during childhood, the molecular mechanism underlying BMF has remained elusive for a long time and is still a matter of debate.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
Current and Novel Directions in Fanconi Anemia Treatment Methods - a Literature Review
AbstractFanconi anemia is a genetically-transmitted disease caused by biallelic inactivating mutations in more than 20 genes. While its main symptoms include severe anemia, other cytopenias and skin pigmentation impairments, the aspect which concerns both patients and caregivers is the connection between Fanconi anemia and the development of several malignancies, especially breast, skin and blood-related cancers, as well as squamous cell carcinomas. Current treatment methods rely on anemia correction through stem cell transplantation, however it has become more and more evident that modern and more efficient therapies need to be developed. This needs-led literature review provides an overview of the main highlights in Fanconi anemia current and emerging therapeutic directions in order to improve the patients’ quality of life.
The Keio Journal of Medicine · 1998 · 0 citations · open access
Molecular Approaches to the Treatment of Fanconi Anemia: Recent Advances.
AbstractFanconi anemia (FA) is an autosomal recessive disorder that leads to aplastic anemia. Cells from FA patients are abnormally sensitive to DNA cross-linking agents such as mitomycin C. FA consists of at least five subgroups (FA-A through-E). The genes defective in the FA-C and FA-A groups have recently been cloned. Transfection of the normal FA gene into mutant cells corrects the hypersensitivity to DNA cross-linking agents and improves cell viability in vitro. The function of the FA gene products is still unclear, however. For patients lacking a compatible bone marrow transplantation donor, an experimental trial of gene therapy for group C FA is ongoing at the National Institutes of Health.
Zenodo (CERN European Organization for Nuclear Research) · 2016 · 0 citations · open access
Fanconi Anaemia: A Review
AbstractFanconi anaemia is a rare genetic disorder which leads to bone marrow failure and results in<br> decreased production of all types of blood cells. The frequency of occurrence is greater in South-<br> African Africaners,sub-saharan blacks, and spanish gypsies than in the overall world<br> population. This rare genetic disease occurs when two people with the recessive gene have<br> children. There is no cure available for falconi anaemia,the treatment for falconi anaemia is<br> symptomatic.<br> Keywords: fanconi anemia,rare genetic disease,growth factors
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
